Join to access to all OVN content. Join for Free
The Art of Story Telling for Impactul Engagement
storytelling in medical affairs engaging Key Opinion Leaders effective storytelling techniques building relationships with KOLs impactful communication in MSLs

The Art of Story Telling for Impactul Engagement


Share This Article


Summary

In this episode, Angela Valadez joins Tom Caravela to explore the power of storytelling in medical affairs. Angela shares her journey and emphasizes the critical role storytelling plays in engaging Key Opinion Leaders (KOLs). She discusses the benefits and key elements of effective storytelling, offering practical techniques for MSLs during KOL meetings. Angela shares personal experiences and best practices, highlighting storytelling as a means to build relationships and facilitate two-way dialogues. The conversation also touches on using storytelling to request referrals and combining it with data for impactful communication. The episode concludes with actionable tips and resources for MSLs.

Angela Valadez, Senior Manager Field Medical Affairs at Regeneron shares insights on how to use story telling to ensure more impactful engagement.

Click for Source
storytelling in medical affairs, engaging Key Opinion Leaders, effective storytelling techniques, building relationships with KOLs, impactful communication in MSLs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions
OVN Avatar Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Article
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years
OVN Avatar Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Article
Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review
OVN Avatar Aaron S. Long, BS; Audrey D. Zhang, MD; Caitlin E. Meyer, MLIS; Alexander C. Egilman, BS; Joseph S. Ross, MD, MHS; Joshua D. Wallach, PhD, MS

Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review

Article
Transforming oncology: Five frontiers driving progress in cancer care
Partner Avatar iNIZIO

Transforming oncology: Five frontiers driving progress in cancer care

Article
Virtual Oncology MSL Team Increases KOL Engagement by 120%
Partner Avatar iNIZIO

Virtual Oncology MSL Team Increases KOL Engagement by 120%

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Explore OVN